Home Portfolio Strategy Team News Contact Moving healthcare forward 5AM’s portfolio of advanced life science technologies is diversified within the healthcare industry’s biopharmaceutical, drug delivery technology and research instrument sectors. We support companies that are working to solve important healthcare needs via cutting-edge breakthroughs in medicine and science. Our portfolio companies spearhead novel approaches to diagnose, prevent and treat a wide range of medical conditions. ALL ACQUIRED & IPOS ACTIVE PRIVATE 5AM Portfolio Companies Achaogen (AKAO) is a biopharmaceutical company developing small molecule therapeutics to treat infections caused by multi-drug resistant bacteria. IPO in March 2014. IPO - MARCH 2014 Akouos (AKUS) is a biotechnology company developing novel gene therapies for the treatment of monogenic forms of congenital deafness. IPO - JUNE 2020 Alexza (ALXA) is a biopharmaceutical company developing drugs for local and systemic delivery through the lung. IPO - MARCH 2006 Ambrx is a biopharmaceutical company which integrates recombinant protein synthesis with medicinal chemistry to develop protein drugs for a range of therapeutic areas. ACQUIRED - JUNE 2015 Aprea (APRE) is a biopharmaceutical company developing small molecule therapeutics for the treatment of cancer by reactivating mutant p53 tumor suppressor function. IPO - OCTOBER 2019 Artiva Biotherapeutics is an oncology company focused on developing and commercializing allogeneic natural killer (NK) cell therapies to treat cancer. Arvinas (ARVN) is a biopharmaceutical company developing small molecule therapeutics that target protein degradation with applications in cancer and other diseases. IPO - SEPTEMBER 2018 Audentes, now Astellas Gene Therapies, a biotechnology company developing viral-based gene therapy for serious, rare diseases including genetic musculoskeletal disorders. Acquired by Astellas in December 2019. ACQUIRED - DECEMBER 2019 Bellerophon (BLPH) is a clinical-stage biopharmaceutical company developing novel drugs and devices for the treatment of cardiopulmonary and cardiac diseases. IPO - FEBRUARY 2015 Bird Rock Bio is a clinical-stage biopharmaceutical company developing biologic therapies for the treatment of rheumatory arthritis and liver disease. BlueLight Therapeutics is a pre-clinical stage company using its proprietary structure-based platform to discover small molecules against difficult-to-drug targets. Cabaletta Bio (CABA) is a biopharmaceutical company focused on the discovery and development of T cell therapies for B cell-mediated autoimmune diseases IPO - OCTOBER 2019 Calibrium is a biopharmaceutical company developing next generation insulins to treat diabetes and obesity. Acquired by Novo Nordisk (NVO) in August 2015. ACQUIRED - AUGUST 2015 Camp4 is a preclinical biotech company with core thesis to restore healthy gene expression in diseased cells by programmable modulation of a new class of RNA. Cellular Research is a life science instrument company developing high resolution systems for the investigation of single cells and limited samples. Acquired by Becton Dickinson (BDX) in August 2015. ACQUIRED - AUGUST 2015 Ceterix is a medical device company developing products to improve outcome for minimally invasive arthroscopic surgeries. ACQUIRED - DECEMBER 2018 Chrono was a biopharmaceutical company developing wearable and programmable therapeutics leveraging novel drug delivery technologies. Cidara (CDTX) is a clinical-stage biopharmaceutical company developing therapeutics for serious fungal infections. IPO - APRIL 2015 CinCor is a clinical-stage biopharmaceutical company with a mission to advance clinical candidates in the area of cardiovascular disease. Cleave is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics that target protein homeostasis pathways for the treatment of cancer. Crinetics (CRNX) is a biopharmaceutical company developing oral small molecule therapeutics for endocrine diseases. IPO - JULY 2018 DVS is a life science instrument company commercializing a mass cytometry for characterizing individual cells based on cell surface proteins. Acquired by Fluidigm (FLDM) in February 2014. ACQUIRED - FEBRUARY 2014 Enliven Therapeutics is a precision oncology company developing best in class and first in class small molecule therapies to extend and improve patient lives Ensoma is a biotechnology company pioneering a next-generation in vivo approach to genetically engineer bone marrow stem cells that will broaden access to curative genetic medicines Entrada (TRDA) is a biotechnology company focused on transforming the treatment of devastating diseases through the intracellular delivery of biologics. IPO - NOVEMBER 2021 Envoy is a drug discovery company with a cell-specific gene expression profiling platform, enabling novel target discovery, such as for the central nervous system. Acquired by Takeda (TKPHF) in November 2012. ACQUIRED - NOVEMBER 2012 Epirus (EPRS) is a global biopharmaceutical company focused on pure-play biosimilar business to improve patient access to cost-effective medicines. Merged into public company in July 2014. MERGED - JULY 2014 Escient Pharmaceuticals develops and manufactures molecules that target a novel class of receptors for the treatment of neuro-immuno-inflammatory and autoreactive diseases. Expansion Therapeutics is a drug discovery and development company focused on RNA-targeted small molecule therapeutics for the treatment of expansion repeat disorders. Flexion (FLXN) is a clinical-stage biopharmaceutical company developing intra-articular sustained release therapeutics for the treatment of musculoskeletal diseases. IPO - FEBRUARY 2014 GlycoEra is a biotechnology company developing a glycoengineering platform to build novel therapeutics that will treat diseases in autoimmune, immuno-oncology, and inflammatory indications. Halio, Inc. is a materials research company developing "adaptive" window technology for residential, automotive and commercial application. Homology Medicines, Inc. (FIXX) translates proprietary, next generation gene editing and gene therapy technology into novel treatments for patients with rare diseases. IPO - MARCH 2018 Ideaya Biosciences uses small molecules as novel personalized cancer therapies, leveraging direct targeting of oncogenic pathways and synthetic lethality – an emerging class of precision medicine targets. IPO - MAY 2019 Igenica is a biopharmaceutical company developing antibodies and antibody-drug conjugates for the treatment of cancer. Ikaria is a commercial-stage biopharmaceutical company developing therapeutic gases for critical care applications. Acquired by Madison Dearborn Partners in February 2014. ACQUIRED - FEBRUARY 2014 Ilypsa is a biopharmaceutical company developing non-absorbed therapeutics for renal and metabolic diseases. Acquired by Amgen (AMGN) in July 2007. ACQUIRED - JULY 2007 Impel Neuropharma (IMPL) is a drug delivery company developing intranasal treatments for central nervous system disorders IPO - APRIL 2021 Incline is a biopharmaceutical company developing a transdermal iontophoretic patch for patient controlled analgesia following surgery. Acquired by The Medicines Company (MDCO) in January 2013. ACQUIRED - JANUARY 2013 Inipharm is a biopharmaceutical company focused on developing small molecules that impact genetically-validated human targets to treat serious diseases of the liver. KaloBios (KBIO) is a biopharmaceutical company developing human antibody therapeutics for oncology and respiratory diseases. IPO'ed in 2013 and is now known as Humanigen, Inc (HGEN). IPO - JANUARY 2013 Kinaset Therapeutics is a biopharmaceutical company developing inhaled small molecules for respiratory diseases Magnetic Insight is a life science tools company developing Magnetic Particle Imaging to accelerate preclinical research with direct translation into the clinic Marcadia is a biopharmaceutical company focused on developing therapeutics for the treatment of diabetes and obesity. Acquired by Roche (RHHBY) in December 2010. ACQUIRED - DECEMBER 2010 Miikana is a clinical-stage biopharmaceutical company developing small molecule therapeutics for cancer. Acquired by EntreMed, a 5AM company, in January 2006. ACQUIRED - JANUARY 2006 Millendo is a biopharmaceutical company developing small molecule therapeutics for polycystic ovarian syndrome, adrenocortical carcinoma and congenital adrenal hyperplasia. MERGED - DECEMBER 2018 Neurogastrx is a biopharmaceutical company developing therapies for the treatment of functional and motility gastrointestinal disorders. NodThera is a biotechnology company focused on the discovery and development of new treatments for diseases driven by chronic inflammation Nohla Therapeutics was a clinical stage company developing ex vivo expanded universal donor cellular therapies, available on demand for treatment of life threatening diseases. Nouscom is a biotechnology company developing genetic vaccines with the ability to target tumor neoantigens delivered through viral vectors. Novira is a biopharmaceutical company developing small molecule therapeutics targeting viral capsid to treat Chronic Hepatitis B. Acquired by Johnson & Johnson (JNJ) in December 2015. ACQUIRED - DECEMBER 2015 Novome is a biotechnology company developing genetically engineered microbial medicines delivering precise activities to treat chronic diseases. Panomics is a research instrument and reagents company which develops cell-based assays and instruments for quantitative multiplexed measurements of molecular events. Acquired by Affymetrix (AFFX) in December 2008. ACQUIRED - DECEMBER 2008 Pear is a biopharmaceutical company combining existing medications with digital software to improve patient outcomes. Pearl is a biopharmaceutical company developing inhalable formulations for the treatment of respiratory diseases such as chronic obstructive pulmonary disease. Acquired by AstraZeneca (AZN) in June 2013. ACQUIRED - JUNE 2013 PhaseRx (PZRX) is a biotechnology company developing polymer-based technology to delivery mRNA nanoparticles for the treatment of orphan diseases. IPO - MAY 2016 Portal is a biopharmaceutical company developing needle-free drug delivery system for the injection of large molecules. PNI is a life science instrument and reagent company developing systems for the discovery and development of novel nanoparticles for biomedical use. Acquired by Danaher Corporation in June 2021 ACQUIRED - MAY 2021 Pulmatrix (PULM) is a pharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases. Merged into public company in June 2015. MERGED - JUNE 2015 Purigen is a life sciences instruments and reagents company developing novel systems for integrated sample extraction and preparation for genomics applications. Radionetics is a precision oncology company focused on radiopharmaceutical drug candidates for the treatment of a broad range of oncology indications. Rallybio (RLYB) is a clinical-stage biotechnology company focused on identifying and accelerating the development of transformative breakthrough therapies for patients with severe and rare disorders. IPO - AUGUST 2021 RareCyte offers Precision Biology solutions focused on multiplexed tissue and single cell analysis of cells and tissue with applications in both research and clinical diagnostics. Relypsa (RLYP) is a commercial-stage biopharmaceutical company developing non-absorbed polymeric drugs, including a potassium-binding agent for hyperkalemia associated with cardiovascular and renal diseases. IPO - NOVEMBER 2013 Rennovia was a materials research company developing chemocatalytic processes for converting biorenewable feedstocks into high value and commodity chemicals. Scientist.com is a marketplace solution for accelerating the pace of pharmaceutical research and development. scPharmaceuticals (SCPH) is a biopharmaceutical company developing therapeutics with enhanced drug delivery using a convenient, self-administering subcutaneous micropump technology. IPO - NOVEMBER 2017 Semprus is a medical device company developing permanent antimicrobial and anti-biofouling surfaces for use on indwelling devices. Acquired by Teleflex (TFX) in May 2012. ACQUIRED - MAY 2012 Soteria is a biotherapeutics company developing a next generation of bispecific T-cell engagers to treat patients with solid tumor cancers. Spyryx was a biopharmaceutical company developing inhaled small peptide therapeutics for lung diseases, in particular cystic fibrosis and COPD. Synosia is a biopharmaceutical company developing and commercializing products for neurodegenerative and psychiatric disorders. Acquired by Biotie, a 5AM company, in February 2011. ACQUIRED - FEBRUARY 2011 TMRW is the world’s first and only integrated platform for automated, software-guided cryospecimen management. With ivfOS™, TMRW provides 100% chain of custody to safeguard the precious eggs and embryos used in IVF. VBI Vaccines is a biopharmaceutical company developing vaccines against Cytomegalovirus and other pathogens. Merged into public company in July 2014. MERGED - JULY 2014 Viveve (VIVE) is a medical device company commercializing a non-surgical, non-ablative medical device for use in women's health. Merged into public company in September 2014. MERGED - SEPTEMBER 2014 Vor Biopharma (VOR) is a biotechnology company engineering hematopoietic stem cells for transplant in the treatment of hematological malignancies. Wildcat is a materials research company developing advanced battery materials for consumer and industrial applications. © 2021 5AM Venture Management LLC Investor Login Contact Us Terms of Use Privacy Policy